Core Viewpoint - The document outlines the decision-making system for related party transactions of Nanjing Haichen Pharmaceutical Co., Ltd, ensuring fairness, transparency, and protection of investors' rights, particularly for minority shareholders [1][2]. Group 1: Related Party Definition - Related parties include both legal entities and natural persons that have control or significant influence over the company [3][4]. - Legal entities are considered related if they are controlled directly or indirectly by the company or its major shareholders [4][5]. - Natural persons are considered related if they hold more than 5% of the company's shares or are part of the company's management [5][6]. Group 2: Related Party Transactions - Related party transactions involve the transfer of resources or obligations between the company and its related parties, including asset purchases, financial support, and management contracts [6][7]. - Certain transactions, such as cash subscriptions for securities, may be exempt from disclosure and approval processes [7][8]. Group 3: Decision-Making Procedures - The company must ensure that related party transactions do not harm the interests of non-related shareholders and must follow fair pricing principles [8][9]. - Related parties must abstain from voting on matters where they have a conflict of interest during board and shareholder meetings [9][10]. - Transactions exceeding a specified threshold must be evaluated by independent financial advisors and submitted for shareholder approval [10][11]. Group 4: Disclosure and Reporting - The company is required to disclose related party transactions in its annual and semi-annual reports, categorizing them appropriately [11][12]. - Any changes to ongoing related party agreements must be submitted for board or shareholder approval [12][13]. Group 5: Prohibitions and Restrictions - The company is prohibited from providing financial assistance to related parties, with specific exceptions for certain joint ventures [13][14]. - Guarantees provided to related parties must be disclosed and approved by the board and shareholders [14][15].

南京海辰药业股份有限公司 独立董事工作制度 （2025 年【6】月） 第一章 总则 第一条 为完善南京海辰药业股份有限公司(以下称"公司")治理结构，规 范公司运作，更好的维护公司整体利益，保障全体股东特别是中小股东的合法权 益不受损害，根据《中华人民共和国公司法》 （以下称"《公司法》"）、 《上市公司 独立董事管理办法》（以下简称"《管理办法》"）、《上市公司独立董事履职指引》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《规范运作》"）、 《深圳证券交易所创业板股票上市规则》 （以下简称 "《上市规则》"）《独立董事和审计委员会履职手册》以及《公司章程》（以下称 "《章程》"）的规定，特制定本独立董事工作制度（以下称"本制度"）。 第二条 独立董事系指不在公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断的关系的董事。 第三条 公司目前设独立董事 3 名。如果《章程》规定的董事会成员人数发 生变更，则公司董事会成员中应当有三分之一以上（包括三分之一）是独立董事， 且至少包括一名会计专业 ...

General Principles - The external guarantee system of Nanjing Haichen Pharmaceutical Co., Ltd. aims to standardize external guarantee behavior, effectively control guarantee risks, and protect shareholders' legal rights [2][3] - The company and its controlling shareholders, directors, and senior management must adhere to the regulations of this system and exercise caution in external guarantees [2][3] Definition and Scope - "External guarantee" refers to the guarantees provided by the company for others, including guarantees for its controlling subsidiaries, excluding guarantees for its own debts [2][3] - A "controlling subsidiary" is defined as a company where the company holds more than 50% of the shares or can control the majority of the board members [3] Principles of External Guarantees - External guarantees must follow principles of equality, voluntariness, fairness, integrity, mutual benefit, strictness, prudence, safety, legality, and standardized operation [3][4] - No individual or entity, including controlling shareholders and related parties, may force the company to provide guarantees [4] Approval Procedures - External guarantees must be uniformly managed by the company, and subordinate departments are prohibited from providing guarantees independently [4][5] - Any external guarantee must be approved by the board of directors and the shareholders' meeting [5][6] Conditions for Providing Guarantees - The company may provide guarantees to entities with independent legal status and strong debt repayment capabilities under specific conditions [9] - Guarantees must require the counterparty to provide counter-guarantees, ensuring the counterparty has the actual capacity to bear the obligation [10] Investigation of the Guaranteed Party - The company must investigate the credit status of the guaranteed party and require them to provide essential documentation, including financial reports and legal compliance statements [11][12] - The company can only provide guarantees if the guaranteed party meets specific credit conditions, such as being a legally established entity with good repayment ability [12][13] Risk Management - After signing a guarantee contract, the finance department is responsible for monitoring and managing subsequent matters related to the guarantee [34] - The company must take necessary remedial measures if the guaranteed party fails to fulfill their debt obligations [35][36] Disclosure Requirements - The company must disclose approved external guarantees on the Shenzhen Stock Exchange website and other media as per regulatory requirements [39] - Timely disclosure is required if the guaranteed party fails to repay debts or faces bankruptcy [40] Responsibilities of Personnel - All directors must carefully manage and control the risks associated with external guarantees and may bear joint liability for losses caused by violations [41][42] - Any unauthorized signing of guarantee contracts by relevant personnel that results in losses to the company will require them to compensate for the losses [42][43]

南京海辰药业股份有限公司 累积投票制实施细则 第一条 为进一步完善公司法人治理结构，规范公司董事的选举行为， 保证股东充分行使权力，根据《公司法》《证券法》及《公司章程》的有关规定， 特制定本实施细则。 第二条 本细则所指累积投票制，是指公司股东会选举两名及两名以上 董事时，出席股东会的股东所拥有的投票权等于其所持有的股份总数乘以应选董 事人数之积，出席会议股东可以将其拥有的投票权全部投向一位董事候选人，也 可以将其拥有的投票权分散投向多位董事候选人，按得票多少依次决定董事人选。 第三条 本实施细则所称"董事"包括独立董事和非独立董事。由职工 代表担任的董事由公司职工民主选举产生或更换，不适用于本实施细则的相关规 定。 第四条 在股东会上，拟选举两名及两名以上的董事时，董事会应当在 召开股东会通知中，表明该次董事选举采用累积投票制。股东会仅选举一名董事 时，不适用累积投票制。 第五条 股东会对董事或候选人进行表决前，大会主持人应明确告知与 会股东对候选董事实行累积投票方式，董事会必须置备适合实行累积投票方式的 选票。董事会秘书应对累积投票方式、选票填写方法做出说明和解释。 第二章 董事的选举及投票 第六条 采 ...

美诺华 20250625 摘要 美诺华正推进创新益生菌药物 389 产品，该产品旨在通过调节肠道菌群， 实现降糖、减重等效果，计划以保健品形式在欧洲注册，并通过跨境电 商等方式进入国内市场，预计最快 2026 年第一季度实现商业化销售。 389 产品目前定位为非药产品，目标市场包括保健品、食品添加剂和新 食品成分。公司计划先通过保健品或新食品成分的审批，再进行小规模 临床试验，以反推产品的有效性，未来或将开发双靶或三靶药物。 389 产品在欧洲和美国市场的注册及上市时间进度方面，安全性实验预 计需要六个月时间，最早可能在 2026 年第一季度上市。在安全性实验 结束后，将以数据模型及佐证材料申报备案。 美诺华对 389 产品的市场空间估算主要基于两类人群：一是使用规划类 生物治疗药物后进入戒断期的人群，二是希望减肥但不愿意接受打针和 吃药的人群，预计前者市场规模可达 50~60 亿美元/年。 美诺华已对 J389 产品进行了深度专利保护，并已递交了专利申请，预计 两周内会获得专利号。公司与美国和欧洲合作方签订了许可协议，后续 在欧洲注册、安全性实验等费用均由合作方承担，美诺华享有约 8%的 收入分成。 Q&A ...

Group 1 - The core viewpoint of the announcement is to establish a standardized external guarantee system to control guarantee risks and protect shareholders' rights [1][2] - The external guarantee is defined as the company providing guarantees for others, excluding guarantees for its own debts [1] - The total amount of external guarantees includes guarantees provided by the company to its subsidiaries and those provided by subsidiaries to third parties [1] Group 2 - The guarantee system emphasizes principles such as equality, voluntariness, fairness, integrity, mutual benefit, strictness, prudence, safety, legal compliance, and standardized operations [1] - Guarantees can only be provided to entities with independent legal status and strong debt repayment capabilities, and must include counter-guarantees from the other party [1][2] - The approval process for guarantees requires board review and timely disclosure, with certain guarantees needing shareholder approval based on specific conditions [2] Group 3 - Guarantee contracts must be in writing and include multiple specified clauses, with a review of relevant content during contract formation [2] - The company has implemented various measures for guarantee risk management, including oversight by the finance department and pursuing recovery after fulfilling guarantee obligations [2] - The system clarifies the responsibilities of directors and senior executives in external guarantees, emphasizing the independence of guarantee decision-making by controlling shareholders [2]

富祥药业2024年公司期间费用为2.57亿元，较上年同期减少6221.26万元；期间费用率为21.80%，较上年同期上升 1.98%。其中，销售费用同比减少52.50%，管理费用同比减少13.42%，研发费用同比减少23.39%，财务费用同比增长 2.50%。 瑞财经 钟鸣辰近日，富祥药业(SZ300497)发布2024年年度报告，同比营收利润双降。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 1,177,846,602.65 | 1.609.669.988.35 | -26.83% | 1.647,263,426.90 | | 归属于上市公司股东 的净利润(元) | -272.100.550.53 | -200,800,049.29 | -35.51% | -141,471,326,16 | | 归属于上市公司股东 的扣除非经常性损益 的净利润(元) | -304,529,910.90 | -197.594.934.26 | -54.12% | -69,199,849.10 | | 经 ...

【消息面】 每日市场观察 2025 年 6 月 26 日 【今日关注】 指数三连阳，万得全 A 指数快速突破前期整理平台。成交量连续放大， 已经达到年内较高水平。量价齐升的走势，初步构建了年内少见的良性 技术形态。行业上，非银金融涨势加速，而银行板块已经呈现连续的强 势，尤其是大型国有银行的上涨，可能反映出长线资金的持续进入。消 息面上，部分公司开始披露中报业绩情况，中东局势趋于稳定，国内大 型券商子公司获得香港证监会批准，将现有交易牌照升级，以及六部门 发布金融支持扩消费 19 条，较多的利好信息提振了整体的市场情绪。 市场风险偏好整体提升，指数的技术层面初步形成对前期整理平台的突 破形态。重点关注成交量变化较为明显的计算机，军工，电子，电力设 备等板块。 【市场回顾】 市场概况：6 月 25 日，市场全天震荡拉升，沪指创年内新高，创业板 指涨近 3%。截至收盘，沪指涨 1.03%，深成指涨 1.72%，创业板指涨 3.11%。 【资金面】 主力资金流向：6 月 25 日，上证净流入 315.72 亿元，深证净流入 325.54 亿元。行业板块方面，主力资金流入前三的板块为证券、软件开发、电 池，主力资金流 ...

金十图示：2025年06月26日（周四）富时中国A50指数成分股今日收盘行情一览：银行股午后上涨，普遍飘红，保险股维持跌势 保险 中国太保 队 中国人保 中国平安 ■ 3980.16亿市值 3621.10亿市值 10485.45亿市值 10.43亿成交额 28.89亿成交额 7.30亿成交额 57.58 37.64 9.00 -0.40(-1.05%) -0.30(-0.52%) -0.13(-1.42%) 酸酒行业 XD贵州茅 山西汾酒 五粮液 17838.01亿市值 2191.67亿市值 4647.45亿市值 19.97亿成交额 49.56亿成交额 10.69亿成交额 179.65 119.73 1420.00 +0.85(+0.48%) -0.45(-0.37%) +11.74(+0.83%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2340.72亿市值 2548.57亿市值 3294.75亿市值 14.13亿成交额 55.90亿成交额 42.74亿成交额 610.50 141.75 437.91 +3.76(+2.72%) -3.67(-0.83%) -0.61(-0.10%) 汽车整车 ...

Core Viewpoint - The company aims to enhance its compliance management system to ensure legal and regulatory adherence, mitigate compliance risks, and support sustainable development [1][2][4]. Compliance Management Framework - The compliance management system applies to the company and its subsidiaries, including wholly-owned, controlled, and actual controlled enterprises [1]. - The system emphasizes adherence to national laws, regulations, industry standards, and internal policies [1][2]. Key Areas of Focus - The company will prioritize compliance in critical areas such as anti-commercial bribery, anti-monopoly, and fair competition [2][4]. - There will be a strong emphasis on contract management, ensuring legality and procedural correctness [3][4]. Risk Management - A comprehensive management system will be established to prevent violations, with adjustments made to investment plans in response to significant changes in external environments or project conditions [2][4]. - The company will conduct regular compliance risk assessments and implement preventive measures [6][7]. Training and Awareness - Compliance training will be mandatory for management and key personnel to foster a culture of compliance [9]. - Employees will be required to sign compliance commitments to reinforce the importance of legal and ethical conduct [9][10]. Monitoring and Reporting - The compliance department will oversee the implementation of compliance requirements and conduct investigations into violations [6][11]. - Any significant compliance incidents must be reported to the relevant departments within two working days [7][11]. Accountability and Enforcement - The company will establish clear accountability standards for compliance breaches, with potential disciplinary actions for violations [10][11]. - Whistleblower protections will be in place to encourage reporting of compliance issues without fear of retaliation [10][11].